We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Monsanto Ties Up with NRGene to Boost Technology Platform
Read MoreHide Full Article
Monsanto Company and NRGene recently entered into a non-exclusive, multi-year global licensing agreement. This deal is based on NRGene’s premium genome-analysis technology. Under its regime, Monsanto would be predicting, comparing and selecting the best variation of genetic makeup from the massive data sets of genomic, genetic and trait information base of NRGene.
Over the last three months, Monsanto’s shares recorded a return of 5.65% – outperforming 4.89% return provided by the Zacks categorized Agricultural/Products industry.
Inside the Headlines
Monsanto uses high quality data analytics technologies for strengthening the research and development platform of its business. These technical know-how helps the company offer non-imitable varieties of high-yielding seed and hybrids to the farmers.
By utilizing NRGene’s GenoMAGIC, Monsanto intends to make plant breeders’ decisions and analysis more comprehensive in the near term. NRGene’s unique genome-analysis technology, such as GenoMAGIC, has been created by several skilled software engineers, algorithm designers, plant geneticists and plant breeders.
Such technologies are used by seed companies and prominent research & academic institutions around the world. Notably, usage of GenoMAGIC would boost Monsanto’s capability in domains of trait discovery, genome selection and genome enhancement.
This Zacks Rank #2 (Buy) company’s major annual research & development investment is focused on plant breeding through the usage of popular genome analysis technologies such as GenoMAGIC. Thus, such technological pacts would likely enhance Monsanto’s existing product portfolio moving ahead.
Stocks to Consider
Some other favorably placed stocks within the industry are listed below:
The Chemours Company (CC - Free Report) also boasts a Zacks Rank #1 and has a whopping average earnings surprise of 153.83% for the four trailing quarters.
CF Industries Holdings, Inc. (CF - Free Report) has an average earnings surprise of 18.83% for the last four quarters, flaunting a Zacks Rank #1.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 ""Strong Buy"" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 ""Strong Sells"" and other private research.See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Monsanto Ties Up with NRGene to Boost Technology Platform
Monsanto Company and NRGene recently entered into a non-exclusive, multi-year global licensing agreement. This deal is based on NRGene’s premium genome-analysis technology. Under its regime, Monsanto would be predicting, comparing and selecting the best variation of genetic makeup from the massive data sets of genomic, genetic and trait information base of NRGene.
Over the last three months, Monsanto’s shares recorded a return of 5.65% – outperforming 4.89% return provided by the Zacks categorized Agricultural/Products industry.
Inside the Headlines
Monsanto uses high quality data analytics technologies for strengthening the research and development platform of its business. These technical know-how helps the company offer non-imitable varieties of high-yielding seed and hybrids to the farmers.
By utilizing NRGene’s GenoMAGIC, Monsanto intends to make plant breeders’ decisions and analysis more comprehensive in the near term. NRGene’s unique genome-analysis technology, such as GenoMAGIC, has been created by several skilled software engineers, algorithm designers, plant geneticists and plant breeders.
Such technologies are used by seed companies and prominent research & academic institutions around the world. Notably, usage of GenoMAGIC would boost Monsanto’s capability in domains of trait discovery, genome selection and genome enhancement.
This Zacks Rank #2 (Buy) company’s major annual research & development investment is focused on plant breeding through the usage of popular genome analysis technologies such as GenoMAGIC. Thus, such technological pacts would likely enhance Monsanto’s existing product portfolio moving ahead.
Stocks to Consider
Some other favorably placed stocks within the industry are listed below:
BASF SE (BASFY - Free Report) has an average earnings surprise of 34.34% for the last four quarters and sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Chemours Company (CC - Free Report) also boasts a Zacks Rank #1 and has a whopping average earnings surprise of 153.83% for the four trailing quarters.
CF Industries Holdings, Inc. (CF - Free Report) has an average earnings surprise of 18.83% for the last four quarters, flaunting a Zacks Rank #1.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 ""Strong Buy"" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 ""Strong Sells"" and other private research. See these stocks free >>